Shares of Profusa ended Monday’s session at $4.53, representing a 27% gain, then rocketed an additional 77% during after-hours trading to reach $8.02. When pre-market trading commenced Tuesday, the stock had climbed 95.6%, nearly doubling from Monday’s closing price.
Profusa, Inc. Common Stock, PFSA
The catalyst behind this surge is largely structural. Profusa implemented a 1-for-4 reverse stock split that became effective at 12:01 a.m. ET on August 17, marking the company’s third such action in 2026. This came on the heels of a 1-for-25 consolidation completed July 7.
The consolidation slashed outstanding shares from 2,422,906 down to roughly 605,726. A fresh CUSIP identifier was issued, with Tuesday’s pre-market representing the first trading session where participants fully incorporated the revised share structure.
When the available float becomes this compressed, minimal trading activity can trigger substantial price fluctuations. Even limited buying interest translates into significant percentage gains, creating an environment that attracts short-term momentum-focused traders.
Separate from the split dynamics, Profusa has been constructing an M&A storyline that maintains heightened speculative attention. In early August, the firm entered into an option agreement targeting the acquisition of G3 Vision Labs, a diagnostics company already generating commercial revenue.
Additionally, a letter of intent remains outstanding for acquiring the PanOmics multi-omics diagnostics platform. While neither transaction has reached completion, the M&A developments provide traders with fundamental talking points beyond the technical aspects of share consolidation.
A delayed quarterly filing with the SEC, announced on August 14, also attracted increased scrutiny to the stock during the days preceding this price action. While delayed filings don’t automatically signal problems, they frequently draw heightened market attention.
The general market backdrop offered zero assistance for this rally. The Nasdaq dropped 1.3% while the S&P 500 declined 0.5% during the same period. This price movement was entirely company-specific in nature.
Profusa specializes in continuous biochemistry monitoring technology, including its Lumee Oxygen and Lumee Glucose monitoring systems. No industry-wide developments in digital health or biointegrated sensor technology emerged to justify the price surge.
The company issued no earnings announcement or significant revenue disclosure. The dramatic price action resulted from the convergence of an extremely limited float, reverse split mechanics, and speculative trading momentum.
PFSA concluded Monday’s regular session at $4.53 before advancing to $8.02 in after-hours activity, representing a 77% session gain before pre-market trading drove shares even higher.
The post Profusa (PFSA) Stock Soars 96% Following Third Reverse Split in 2026 appeared first on Blockonomi.
